in brief Health services company CSC has announced that it has been given the go-ahead from the European Commission for its iSoft buy.
The company said that the clearance was the last regulatory consent required for the transaction to occur, although it is still subject to gaining shareholder and court assent in Australia.
The acquisition has experienced some resistance in the courts, with founder Gary Cohen voicing his concerns that CSC's offer undervalued the company, and sought to stall the sale to seek better offers. There was also action over the price to be paid for convertible notes.
CSC believes that the acquisition will aid its research and development efforts, and will help the company to grow.